A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05277493

Enrollment

500

Registered

2022-03-14

Start date

2022-03-30

Completion date

2025-09-30

Last updated

2022-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AL Amyloidosis

Brief summary

The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* 18 years and older * newly diagnosed or refractory/relapsed AL amyloidosis * treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy

Exclusion criteria

* co-diagnosis of multiple myeloma or Waldenström's macroglobulinemia

Design outcomes

Primary

Measure	Time frame
Hematologic complete response at 3 months	3 months

Countries

China

Contacts

Primary ContactDaobin Zhou, MD

zhoudb@pumch.cn69155020

Outcome results